CONTINGENT INEFFICACY AND CONTINGENT TOLERANCE

偶然的无效性和偶然的耐受性

基本信息

  • 批准号:
    5203747
  • 负责人:
  • 金额:
    --
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
  • 资助国家:
    美国
  • 起止时间:
  • 项目状态:
    未结题

项目摘要

This project studies the phenomenology and biological substrates of contingent drug effects. Using a kindling paradigm, we have demonstrated that the anticonvulsant efficacy of carbamazepine and other drugs can be manipulated by temporal factors relating to drug administration and seizure presentation. Significant findings include demonstration of the following: 1) contingent inefficacy, whereby the contingent presentation of carbamazepine during amygdala kindling seizure development (i.e., before, but not after electrical stimulation), while not affecting kindling development, produced a subsequent refractoriness to carbamazepine's anticonvulsant effects on completed kindled seizures (when it should have been effective); 2) contingent tolerance, in which animals that have completed kindled seizures develop tolerance to carbamazepine following repeated administration of the drug prior to, but not after, each electrical stimulation; 3) contingent tolerance reversal by treatment with carbamazepine after the kindled seizures or kindled seizures alone (no drug), but not by time off (no drug or kindling stimulation) or drug treatment alone (no seizures); 4) contingent refractoriness to valproate, in which animals hat were kindled with the contingent presentation of valproate before each stimulation (which slowed kindling development), became valproate non-responsive; those kindled with non-contingents-exposure to valproate remained sensitive to its anticonvulsant effects; 5) cross tolerance to carbamazepine in valproate-refractory rats; nd reversibility of this effect by kindling the animals with valproate after each stimulation for one week; 6) contingent cross tolerance between carbamazepine and a ligand that binds the peripheral-type benzodiazepine receptor, and valproate, but not between carbamazepine and diazepam, clonazepam or phenytoin; 7) alterations in seizure threshold which mirror the changes in responsivity to carbamazepine; 8) slowing of contingent tolerance development by non- contingent drug presentation or by kindling the rats at lower stimulation currents, but not by higher doses of carbamazepine; 9) modulation of kindled seizure thresholds by different levels of kindling stimulation; 10) no effect of the NMDA antagonist MK-801 or the calcium channel antagonist nimodipine on contingent tolerance development and 11) a number of neurochemical correlates of contingent tolerance which represent a loss of a subset of seizure-induced adaptations in the GABA-A system as well as in peptide mRNAs, trophic factors, and immediate early genes; 11) neurochemical correlates of contingent tolerance to diazepam which overlap with but are not identical to those observed in carbamazepine tolerance; 12) slower tolerance development to combined treatment with carbamazepine (15 mg/kg) and valproate (low dose--150 mg/kg) compared to either one alone.
本项目研究的是植物的现象学和生物基质

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

S R WEISS其他文献

S R WEISS的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('S R WEISS', 18)}}的其他基金

BEHAVIORAL SENSITIZATION
行为敏感化
  • 批准号:
    2578747
  • 财政年份:
  • 资助金额:
    --
  • 项目类别:
PHARMACOLOGICAL KINDLING
药理点燃
  • 批准号:
    3881014
  • 财政年份:
  • 资助金额:
    --
  • 项目类别:
PHARMACOLOGICAL KINDLING
药理点燃
  • 批准号:
    3845320
  • 财政年份:
  • 资助金额:
    --
  • 项目类别:
BEHAVIORAL SENSITIZATION
行为敏感化
  • 批准号:
    3759456
  • 财政年份:
  • 资助金额:
    --
  • 项目类别:
CONTINGENT INEFFICACY AND CONTINGENT TOLERANCE
偶然的无效性和偶然的耐受性
  • 批准号:
    3759459
  • 财政年份:
  • 资助金额:
    --
  • 项目类别:
CONNTINGENT INEFFICACY AND CONTINGENT TOLERANCE
或有的无效性和或有的耐受性
  • 批准号:
    3881016
  • 财政年份:
  • 资助金额:
    --
  • 项目类别:
PHARMACOLOGICAL AND BIOCHEMICAL STUDIES OF AMYGDALA KINDLING
杏仁核点燃的药理学和生物化学研究
  • 批准号:
    5203746
  • 财政年份:
  • 资助金额:
    --
  • 项目类别:
CONTINGENT INEFFICACY AND CONTINGENT TOLERANCE
偶然的无效性和偶然的耐受性
  • 批准号:
    3781442
  • 财政年份:
  • 资助金额:
    --
  • 项目类别:
PHARMACOLOGICAL KINDLING
药理点燃
  • 批准号:
    3781440
  • 财政年份:
  • 资助金额:
    --
  • 项目类别:
PHARMACOLOGICAL AND BIOCHEMICAL STUDIES OF AMYGDALA KINDLING
杏仁核点燃的药理学和生物化学研究
  • 批准号:
    3881015
  • 财政年份:
  • 资助金额:
    --
  • 项目类别:

相似海外基金

Novel pediatric anticonvulsants for nerve agents
用于神经毒剂的新型儿科抗惊厥药
  • 批准号:
    10004277
  • 财政年份:
    2020
  • 资助金额:
    --
  • 项目类别:
Novel pediatric anticonvulsants for nerve agents
用于神经毒剂的新型儿科抗惊厥药
  • 批准号:
    10475298
  • 财政年份:
    2020
  • 资助金额:
    --
  • 项目类别:
Novel Water-Soluble Adjunct Anticonvulsants for Nerve Agents
用于神经毒剂的新型水溶性辅助抗惊厥药
  • 批准号:
    10013749
  • 财政年份:
    2020
  • 资助金额:
    --
  • 项目类别:
Novel pediatric anticonvulsants for nerve agents
用于神经毒剂的新型儿科抗惊厥药
  • 批准号:
    10693904
  • 财政年份:
    2020
  • 资助金额:
    --
  • 项目类别:
Study on how anticonvulsants affect car driving
抗惊厥药如何影响汽车驾驶的研究
  • 批准号:
    20K17977
  • 财政年份:
    2020
  • 资助金额:
    --
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Novel Water-Soluble Adjunct Anticonvulsants for Nerve Agents
用于神经毒剂的新型水溶性辅助抗惊厥药
  • 批准号:
    10266034
  • 财政年份:
    2020
  • 资助金额:
    --
  • 项目类别:
Novel Water-Soluble Adjunct Anticonvulsants for Nerve Agents
用于神经毒剂的新型水溶性辅助抗惊厥药
  • 批准号:
    10475109
  • 财政年份:
    2020
  • 资助金额:
    --
  • 项目类别:
Novel pediatric anticonvulsants for nerve agents
用于神经毒剂的新型儿科抗惊厥药
  • 批准号:
    10248384
  • 财政年份:
    2020
  • 资助金额:
    --
  • 项目类别:
Prevention of neuropathic pain by antidepressants and anticonvulsants: in vivo patch-clamp analysis
抗抑郁药和抗惊厥药预防神经性疼痛:体内膜片钳分析
  • 批准号:
    24592355
  • 财政年份:
    2012
  • 资助金额:
    --
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Anticonvulsants, ischemic seizures and regeneration in the immature brain
抗惊厥药、缺血性癫痫发作和未成熟大脑的再生
  • 批准号:
    8492175
  • 财政年份:
    2009
  • 资助金额:
    --
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了